Data Integrity in Clinical Trials

by | Jun 14, 2019 | Clinical Trials, FDA, Medical Devices, Pharmaceuticals, Quality Systems, Regulatory

FDA defines data integrity as the completeness, consistency, and accuracy of data. Data Integrity is not a new concept and it has been a matter of concern since the paper and ink era. With the new computerized systems and cloud storage, if system breakdowns or failures would result in the permanent loss of records, a back-up system should be provided. A means of ensuring data protection has become a necessity.

There have been increased citations concerning data integrity violations involved in CGMP FDA inspections. These data integrity related CGMP violations have led to numerous regulatory actions, including warning letters, import alerts, and consent decrees.

Data integrity issues cost the sponsor thousands of dollars because when such issues arise, FDA may require the company to take some extra measures to demonstrate the quality and reliability of their data. These extra measures will cause sponsors a delay in their drug approval process and consequently a delay in getting to market and earning revenue.

Requirements with respect to data integrity in parts 211 and 212 include:1

  • § 211.68 (requiring that “backup data are exact and complete” and “secure from alteration, inadvertent erasures, or loss” and that “output from the computer … be checked for accuracy”).
  • § 212.110(b) (requiring that data be “stored to prevent deterioration or loss”).
  • §§ 211.100 and 211.160 (requiring that certain activities be “documented at the time of performance” and that laboratory controls be “scientifically sound”).
  • § 211.180 (requiring that records be retained as “original records,” or “true copies,” or other “accurate reproductions of the original records”).
  • §§ 211.188, 211.194, and 212.60(g) (requiring “complete information,” “complete data derived from all tests,” “complete record of all data,” and “complete records of all tests performed”)
  • § 211.22, 211.192, and 211.194(a) (requiring that production and control records be “reviewed” and that laboratory records be “reviewed for accuracy, completeness, and compliance with established standards”).
  • §§ 211.182, 211.186(a), 211.188(b)(11), and 211.194(a)(8) (requiring that records be “checked,” “verified,” or “reviewed”).

Another important factor to consider within data integrity is an audit trail. An electronic record of creation, modification or archival of a document should be traced back to the who, when and why of the document at the time of performance.

Need to avoid data integrity issues in your next clinical trial? Are you looking to market your new drug and need to conduct clinical trials? Give us a call at 248-987-4497 or email us at

1FDA (Dec 2018) Data Integrity and Compliance With Drug CGMP Questions and Answers Guidance for Industry retrieved on 06/13/2019 from


Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.
Is your product a medical device?

Is your product a medical device?

Many marketed products are classified as medical devices and you would not even know it. Medical devices range from latex gloves and tongue depressors to respirators and heart valves. To determine if the product is considered a medical device by the Food and Drug Administration (FDA) you will need to analyze if your product meets the definition of a medical device per the Food, Drug, and Cosmetic Act1.

Ready to learn more about working with us?

Pin It on Pinterest

Share This